
NEWS RELEASE**IX BIOPHARMA APPOINTS DR. BRIAN KENNEDY
AS NEW SCIENTIFIC ADVISOR**

Singapore, 14 October 2024 – iX Biopharma Ltd (“iX Biopharma” or the “Company”) a specialty pharmaceutical company that develops innovative therapies using its proprietary sublingual drug delivery technologies, is pleased to announce that Dr. Brian Kennedy, PhD, has joined its Scientific Advisory Board (SAB) as a scientific advisor. Dr. Kennedy brings immense expertise in the field of aging and longevity, supporting iX Biopharma’s aim to develop and market NAD+ and other healthspan supplements through its supplements arm, Entity Health.

Dr. Kennedy is a Distinguished Professor in the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Departments of Biochemistry and Physiology. He is the Director of the Healthy Longevity Translational Research Programme in NUS and Director of the Centre For Healthy Longevity, National University Health System (NUHS). Prior to this, he was the President and CEO of the Buck Institute for Research on Aging and he maintained a professorship there through 2020. He served as the Co-Editor-In-Chief at the journal Aging Cell from 2011 to 2021.

Dr. Kennedy is widely recognised for his contributions in the biology of aging and as a visionary committed to translating research discoveries into new ways to delay, detect and prevent human aging and its associated diseases. With a plethora of widely-cited research papers on aging and longevity under his belt, he is regarded as an expert in the science of gerontology.

*"We are delighted to welcome Dr. Kennedy to our Scientific Advisory Board," said **Mr. Eddy Lee, Chairman & CEO** of iX Biopharma. "Dr. Kennedy's partnership is invaluable as we work on developing and commercialising innovative healthspan products like SL-NAD+, Entity Health's NAD+ sublingual wafers. His extensive knowledge in the biology of ageing will be instrumental in advancing our research and clinical trials and his endorsement will bolster our marketing plans. We are confident that his insights will shape and improve our efforts to revolutionise aging science and improve quality of life globally."*

Contact for media:

Eva Tan
Chief Commercial Officer
T: +65 6235 3212
E: eva.tan@ixbiopharma.com

Daniel Chow
Director of Business Development
T: +65 6235 2270
E: daniel.chow@ixbiopharma.com